Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and ...
In March 2026, Indivior Pharmaceuticals reported a new cost impact model in The Journal of Current Medical Research and Opinion showing that monthly extended-release buprenorphine injections ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Nassau County drug rehab now offers monthly Sublocade and Vivitrol injections for opioid and alcohol addiction on Long ...
Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, ...
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
Malachi Castner, 23, said he didn’t always sleep on the Blue Line train to avoid the cold and rain. He didn’t always start his day early by shooting up. He was once a teenager on his high school’s ...
The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results